for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover PharmAsia News
  [0 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 1875-7774
   Published by Informa plc Homepage  [16 journals]
  • Avastin Faces New Rival In Korea As Lynparza Approved
    • Abstract: The launch of AstraZeneca's Lynparza, a targeted therapy for advanced ovarian cancer, in South Korea will give more treatment options for platinum-resistant ovarian cancer patients, but the first PARP inhibitor to be launched in the country will have to go up against well-established rival Avastin.
      PubDate: Thu, 28 Jan 2016 19:45:00 -050
       
  • Understanding Regs Key As CFDA Toughens GMP Enforcement
    • Abstract: The China FDA is substantially beefing up inspections of foreign drug manufacturing sites, showing assertiveness and confidence towards China's own GMP standards after a massive domestic campaign to root out quality violators. For companies eyeing the world's second largest pharma market, staying out of trouble will require keeping on top of local regulatory updates, says an industry insider.
      PubDate: Thu, 28 Jan 2016 18:50:01 -050
       
  • J&J Plays Down China Slowdown, Sees ’16 Bottom-Out
    • Abstract: J&J's growth rate in China nearly halved compared to one year ago, but the world's largest pharma and medtech firm has used the time to tweak and improve its operations and is forecasting a better year ahead.
      PubDate: Thu, 28 Jan 2016 01:05:00 -050
       
  • China, Currency Effects Hit Novartis’s Emerging Market Sales
    • Abstract: Emerging markets presented a mixed bag for Novartis last year, with growth in China continuing to slow in the fourth quarter but increasing in smaller more dynamic countries such as Turkey. Sandoz remained strong in Asia but eye care unit Alcon is set for major changes.
      PubDate: Thu, 28 Jan 2016 00:15:03 -050
       
  • US NIH Resumes Indian Trials, Will Others Follow'
    • Abstract: More than two years after it cut back on Indian clinical trials, the US National Institutes of Health (NIH), the largest public funder of biomedical research in the world, appears to have recommenced activity in the area, albeit on a cautious note.
      PubDate: Wed, 27 Jan 2016 19:20:13 -050
       
  • Turkey Pursues Local Manufacture Of Hepatitis A Vaccine
    • Abstract: While preparing Turkey's legal and business infrastructure for the local production of critical drugs and vaccines, the Ministry of Health has announced that first project will be a hepatitis A vaccine. The work on a related incentives package for possible foreign partners is almost complete and the project will be launched this year.
      PubDate: Tue, 26 Jan 2016 23:30:02 -050
       
  • Election Boost For Taiwan Biopharma Industry'
    • Abstract: Last week’s presidential election in Taiwan saw biotech stocks surge on the back of expectations the island’s newly elected president - a biotech company founder - will rapidly discuss and implement policies positive for the sector as she seeks to position it as a strategic economic growth engine.
      PubDate: Tue, 26 Jan 2016 21:40:00 -050
       
  • Open Innovation A Must, Not A Choice: Hanmi Forum
    • Abstract: Hanmi Pharm has convened a forum in Seoul to discuss open innovation from various perspectives and to explore R&D directions and partnering strategies fit for South Korea's wider pharma industry, and to identify the main challenges along the way. Through the initiative, the firm is aiming to share R&D ideas, bolster its pipeline and seek ways to cooperate with industry, academia and research institutes.
      PubDate: Tue, 26 Jan 2016 20:50:00 -050
       
  • JPM 2016: Cipla Shapes Respiratory Build-Up
    • Abstract: Around a quarter of Cipla's top 50 R&D projects currently underway are in the respiratory segment and the Indian firm says it aims to launch its own differentiated respiratory and oncology pipeline in the US in the "near future."
      PubDate: Tue, 26 Jan 2016 01:55:01 -050
       
  • Market Access Barriers Deterring New China R&D Investment: AmCham
    • Abstract: Market access barriers are deterring 80% of US R&D-intensive industries, including pharma, from investing further in China, and many are pessimistic about the future regulatory environment in the country, says a just released business climate survey.
      PubDate: Tue, 26 Jan 2016 01:05:00 -050
       
  • Sandoz Rituximab Pact Adds To Kyowa Kirin’s Biosimilar Arsenal
    • Abstract: Kyowa Hakko Kirin's acquisition of Japanese rights to Sandoz's version of rituximab marks an expansion of the Japanese company's interests in the biosimilars sector, which it sees as 'important' for its business over the coming years.
      PubDate: Tue, 26 Jan 2016 00:10:01 -050
       
  • Ocata Shareholders Hold Out On Astellas Offer
    • Abstract: Another tender offer deadline has come and gone for Astellas in its pursuit of Boston's Ocata Therapeutics, but the Japanese firm remains committed to pursuing its quarry.
      PubDate: Mon, 25 Jan 2016 19:50:01 -050
       
  • Indian Start-up Vyome Wins Milestone FDA Nod For Acne Studies
    • Abstract: Vyome Biosciences has won FDA clearance to conduct clinical trials in the US with a novel topical acne medicine, becoming one of a new breed of Indian start-ups to do original research.
      PubDate: Mon, 25 Jan 2016 01:55:01 -050
       
  • Approval Clears Way For Evolocumab To Blaze Japan PCSK9 Trail
    • Abstract: Following a positive recommendation late last year, Japan has now issued a formal regulatory approval to Amgen Astellas’s evolocumab, which will blaze a trail as the first PCSK9-targeting biologic to be commercialized in the country.
      PubDate: Mon, 25 Jan 2016 01:10:00 -050
       
  • World Top Scientist Busted For Stealing GSK Secrets
    • Abstract: US prosecutors have laid out yet another case of pharma trade secret theft where very intelligent people apparently made the mistake of thinking they were too smart to get caught.
      PubDate: Sun, 24 Jan 2016 21:25:05 -050
       
  • Janssen, GSK China HIV Approvals Show Increased Transparency
    • Abstract: In a rare move and a further indication of a determination to break away from its past, the China FDA has made timely public announcements of the approval of two new treatments for HIV that it deems to be breakthroughs, although it could be some time before they reach the market.
      PubDate: Thu, 21 Jan 2016 09:20:02 -050
       
  • MARKET PROFILE: Mongolia - Pharma’s Final Frontier'
    • Abstract: Mongolia is a country with a huge territory but relatively small population. In recent years, the country has developed rapidly because of its massive coking coal and copper deposits, with GDP growth of 7.8% in 2014.
      PubDate: Thu, 21 Jan 2016 08:55:02 -050
       
  • Turkey Company Roundup: Novartis Tops R&D, Takeda Expanding
    • Abstract: Novartis, which has emerged as the top pharmaceutical company by R&D investment in Turkey, is asking for more innovation-supporting policies in the country, while Takeda is expanding and plans to introduce new products in oncology this year. Meanwhile, the AIFD industry association has called for policies to increase Turkey’s capacity for drug exports.
      PubDate: Thu, 21 Jan 2016 04:40:05 -050
       
  • Early Approvals Pave Smooth Biosimilar Path For Celltrion, Samsung
    • Abstract: South Korea's Celltrion and Samsung Bioepis are competing hard to grab a slice of the burgeoning global biosimilar market. Celltrion’s Remicade biosimilar has already been widely launched and may only be a step away from entering the US, while Samsung Bioepis has received three regulatory approvals for its biosimilars.
      PubDate: Thu, 21 Jan 2016 03:55:01 -050
       
  • US FDA Posts Agent In Singapore But Other Foreign Offices Close
    • Abstract: The US FDA is consolidating its China offices to allow the regulatory agency to 'strategically focus its resources' but has placed a new agent in Singapore as part of its crime-fighting effort.
      PubDate: Thu, 21 Jan 2016 03:40:06 -050
       
  • WuXi Eyes Growing Biologics Business With New Integrated Center
    • Abstract: An integrated biologics solution center is China's largest CRO WuXi AppTec's first investment completes its going private move. Aiming to provide full range of services to clients developing antibody drugs, WuXi plans more investment within the next 12 months.
      PubDate: Wed, 20 Jan 2016 04:30:01 -050
       
  • India Reports Progress Over EU Drug Ban
    • Abstract: New Delhi says Indian and European regulators have made headway in discussions over an EU ban on certain Indian pharmaceutical products.
      PubDate: Wed, 20 Jan 2016 04:00:01 -050
       
  • European Roll Out For Samsung Bioepis's Etanercept Biosimilar
    • Abstract: After gaining two regulatory approvals for its biosimilars at home last year, South Korea's Samsung Bioepis has now received its first overseas clearance for an etanercept biosimilar, in Europe. Benepali, which will be Europe's first biosimilar version of the fusion protein, is set to enter 31 European markets.
      PubDate: Tue, 19 Jan 2016 12:25:01 -050
       
  • Oscotec's SYK Inhibitor Program Gets Korea Drug Fund Money
    • Abstract: Oscotec is set to accelerate the development of a novel oral rheumatoid arthritis drug, helped by financial support from the state-run Korea Drug Development Fund for a US Phase I clinical trial of the South Korean venture’s spleen tyrosine kinase inhibitor.
      PubDate: Tue, 19 Jan 2016 04:10:01 -050
       
  • JPM 2016: Big Pharma Committed To Emerging Markets Despite Volatility
    • Abstract: What's in store in 2016 for big pharma in emerging markets amid increasing volatility in this sector? A number of top executives shared their views at the recent JP Morgan Healthcare Conference, and the overall message was one of continuing commitment and expansion and need for balance with the rest of the business.
      PubDate: Tue, 19 Jan 2016 03:25:01 -050
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2015